QuantumScape 10-Qquarter ended 2026-06-30

Executive Summary

QuantumScape develops solid-state lithium-metal batteries for automakers, with planned income from battery commercialization and technology licensing but no revenue to date. It is concentrating on QSE-5 cells, automated pilot production and its PowerCo partnership to move from customer samples toward commercial manufacturing. Q2 operating loss narrowed to $106M, largely because depreciation and impairment charges fell rather than because commercialization generated income. The July PowerCo amendment makes partner funding dependent on cell-delivery and validation milestones while reducing maximum program payments to $75.4M. With $859M in cash and marketable securities, QuantumScape has resources to continue development, but the investment case still depends on proving manufacturing consistency and converting customer testing into commercial agreements.

What's Happening in the Business

• Pilot production: QuantumScape inaugurated its highly automated San Jose pilot line in February 2026 and began ramping initial capacity. The line supports QSE-5 development, customer samples and PowerCo collaboration; installation is progress, but not proof of commercial-scale production.

• Product and customer qualification: Automotive customers are testing QSE-5 samples following B1 prototype deliveries in 2025. The approximately 5 amp-hour cell targets energy density above 800 watt-hours per liter and charging from 10% to 80% in under 15 minutes. Its anode-free design and proprietary Cobra separator process aim to reduce manufacturing steps and improve throughput, but quality, reliability, safety and cost still require improvement.

• PowerCo funding reset: After quarter-end, the July amendment replaced cost reimbursement with payments tied to cell delivery and validation over two years. Maximum aggregate program payments fell from $130.7M to $75.4M, including amounts already paid. This is separate from the contemplated licensing arrangement and conditional $130M initial royalty prepayment; neither that prepayment nor future royalties should be treated as secured cash.

• Technical leadership: CTO Timothy Holme will temporarily shift toward long-term R&D from August 2026 through May 2027, with some daily responsibilities moving to other senior technical leaders. He remains CTO and is expected to resume full duties afterward, making execution continuity relevant during the pilot ramp.

Key Financial Highlights

• Expense quality: Q2 R&D expense fell 18% to $82.5M, with $19.2M of combined reductions in impairment and depreciation charges. Materials and stock-based compensation increased, so the expense decline does not establish a comparable reduction in development activity. Management expects costs to rise as commercialization and customer support expand.
• Cash use versus earnings: H1 operating cash outflow was $116M versus a $199M net loss; noncash stock-based compensation of $57.8M and depreciation and amortization of $28.1M explain much of the gap. Capital expenditures of $14.6M brought FCF to $(131)M, versus $(137)M a year earlier.
• Funding reserve: Cash, cash equivalents and marketable securities fell 12% from year-end to $859M. H1 financing included a $10.4M PowerCo capital contribution with no shares issued; this was equity funding, not revenue.
• Dilution: Q2 weighted-average shares increased 9.9% Y/Y, helping loss per share narrow more than net loss. Outstanding restricted and performance stock units create further potential dilution despite lower H1 stock-based compensation.

Risk Assessment

• Manufacturing and qualification: QuantumScape has not produced cells at commercial volume, and limited-sample test results may not translate into acceptable yields, reliability, costs or automotive approval.
• PowerCo dependence: Funding and licensing depend on technical milestones, future demand and a major related party; Volkswagen held approximately 27.3% of voting interests, adding governance influence to commercial concentration.
• Funding and dilution: Significant production is not expected in the near term, while continuing losses and scale-up spending could require additional capital or force reduced development investment.
• Competitive economics: Established lithium-ion producers and better-funded solid-state competitors could improve costs faster than QuantumScape can validate its proposed manufacturing advantages.

What to Watch

• Pilot-line execution: Initial capacity is ramping in San Jose. Later filings should show more consistent separator and cell production and sufficient customer samples; unstable yields, equipment changes or further write-offs would weaken the scale-up case.
• Customer qualification: QSE-5 remains in automotive testing. Progress toward later sample stages and production agreements would validate demand; repeated redesigns or prolonged evaluations without commitments would challenge it.
• PowerCo milestones: The revised program pays for delivery and validation. Payments and progress toward the separate license would demonstrate execution; missed milestones or further restructuring would undermine both funding and commercialization.
• Cash runway: Management says resources cover at least 12 months from the report date. Watch whether technical progress justifies continuing cash use; financing before meaningful validation would increase dilution exposure.